Adial Competitors
| ADIL Stock | USD 3.05 0.07 2.24% |
Adial Pharmaceuticals vs Biocardia Correlation
Very weak diversification
The correlation between Adial Pharmaceuticals and BCDA is 0.46 (i.e., Very weak diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Adial Pharmaceuticals and BCDA in the same portfolio, assuming nothing else is changed.
Moving against Adial Stock
| 0.9 | RBGPF | Reckitt Benckiser | PairCorr |
| 0.89 | MRK | Merck Company Aggressive Push | PairCorr |
| 0.86 | AMKBY | AP Moeller Maersk | PairCorr |
| 0.85 | JNJ | Johnson Johnson | PairCorr |
| 0.85 | AA | Alcoa Corp | PairCorr |
Adial Pharmaceuticals Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Adial Pharmaceuticals and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Adial and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Adial Pharmaceuticals does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Adial Stock performing well and Adial Pharmaceuticals Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Adial Pharmaceuticals' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| NRSN | 4.43 | (0.08) | 0.00 | (0.09) | 0.00 | 12.82 | 34.62 | |||
| ACXP | 4.54 | (1.20) | 0.00 | (0.55) | 0.00 | 10.84 | 49.19 | |||
| MTNB | 5.53 | (0.90) | 0.00 | 1.82 | 0.00 | 11.67 | 39.32 | |||
| BCLI | 3.59 | (0.16) | 0.00 | (0.47) | 0.00 | 9.09 | 24.01 | |||
| APRE | 4.04 | (1.04) | 0.00 | (0.37) | 0.00 | 4.44 | 46.26 | |||
| HCWB | 5.07 | (1.76) | 0.00 | (0.85) | 0.00 | 13.02 | 41.72 | |||
| KPRX | 2.47 | (0.25) | 0.00 | (0.16) | 0.00 | 4.44 | 16.69 | |||
| CDIO | 5.71 | (1.72) | 0.00 | (0.35) | 0.00 | 14.54 | 38.04 | |||
| CELZ | 4.10 | (0.68) | 0.00 | (0.28) | 0.00 | 8.61 | 25.03 | |||
| BCDA | 2.62 | (0.16) | 0.00 | (0.16) | 0.00 | 5.93 | 17.38 |
Cross Equities Net Income Analysis
Compare Adial Pharmaceuticals and related stocks such as Neurosense Therapeutics, Acurx Pharmaceuticals LLC, and Matinas BioPharma Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NRSN | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (2.8 M) | (4 M) | (12.3 M) | (10.1 M) | (10.2 M) | (9.2 M) | (9.6 M) |
| ACXP | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (4.6 M) | (12.7 M) | (12.1 M) | (14.6 M) | (14.1 M) | (12.7 M) | (13.3 M) |
| MTNB | (116.1 K) | (116.1 K) | (116.1 K) | (3.7 M) | (10.2 M) | (9.1 M) | (7.6 M) | (15.5 M) | (14.1 M) | (17.4 M) | (22.4 M) | (23.3 M) | (21 M) | (22.9 M) | (24.3 M) | (21.8 M) | (22.9 M) |
| BCLI | (25.6 K) | (3.9 M) | (3.4 M) | (4.9 M) | (9.2 M) | (8.5 M) | (5 M) | (5 M) | (13.9 M) | (23.3 M) | (31.8 M) | (24.5 M) | (23.7 M) | (17.2 M) | 11.6 M | 10.5 M | 11 M |
| APRE | (3.5 M) | (254 K) | (254 K) | (436.2 K) | (15.2 M) | (15.2 M) | (15.2 M) | (15.2 M) | (15.5 M) | (28.1 M) | (53.9 M) | (36.5 M) | (112.7 M) | (14.3 M) | (13 M) | (11.7 M) | (12.2 M) |
| HCWB | (7.3 M) | (7.3 M) | (7.3 M) | (7.3 M) | (7.3 M) | (7.3 M) | (7.3 M) | (7.3 M) | (7.3 M) | (7.3 M) | (5.8 M) | (12.9 M) | (14.9 M) | (25 M) | (30 M) | (27 M) | (25.7 M) |
| KPRX | (6 M) | (6 M) | (6 M) | (3.9 M) | (1.8 M) | (8.4 M) | (13.3 M) | (13.2 M) | (10.8 M) | (7.1 M) | (6.9 M) | (13.8 M) | (13.6 M) | (12.5 M) | 3.6 M | 3.2 M | 3.4 M |
| CDIO | (605.2 K) | (605.2 K) | (605.2 K) | (605.2 K) | (605.2 K) | (605.2 K) | (605.2 K) | (605.2 K) | (605.2 K) | (605.2 K) | (605.2 K) | (620.4 K) | (4.7 M) | (8.4 M) | (8.4 M) | (7.5 M) | (7.2 M) |
| CELZ | 1.4 K | (24.1 K) | (25.6 K) | (27.3 K) | (28 K) | (30.8 K) | (766.1 K) | (2.7 M) | (13.7 M) | (8.5 M) | (36.3 M) | 19.2 M | (10.1 M) | (5.3 M) | (5.5 M) | (4.9 M) | (5.2 M) |
| BCDA | 135.6 K | 9.7 M | 305 K | 19 K | 234 K | 322 K | (10.3 M) | (12.3 M) | (14 M) | (14.7 M) | (15 M) | (12.6 M) | (11.9 M) | (11.6 M) | (7.9 M) | (7.2 M) | (6.8 M) |
Adial Pharmaceuticals and related stocks such as Neurosense Therapeutics, Acurx Pharmaceuticals LLC, and Matinas BioPharma Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Adial Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Adial Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Adial Pharmaceuticals Competitive Analysis
The better you understand Adial Pharmaceuticals competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Adial Pharmaceuticals' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Adial Pharmaceuticals' competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Adial Pharmaceuticals Competition Performance Charts
Five steps to successful analysis of Adial Pharmaceuticals Competition
Adial Pharmaceuticals' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Adial Pharmaceuticals in relation to its competition. Adial Pharmaceuticals' competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Adial Pharmaceuticals in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Adial Pharmaceuticals' competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Adial Pharmaceuticals, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Adial Pharmaceuticals position
In addition to having Adial Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run World Allocation Funds Thematic Idea Now
World Allocation Funds
Funds or Etfs investing in stocks, bonds, and cash of domestic markets as well as in markets of Canada, Japan, and Europe. The World Allocation Funds theme has 42 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize World Allocation Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Adial Pharmaceuticals Correlation with its peers. For more information on how to buy Adial Stock please use our How to buy in Adial Stock guide.You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adial Pharmaceuticals. If investors know Adial will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Adial Pharmaceuticals assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Adial Pharmaceuticals's market price often diverges from its book value, the accounting figure shown on Adial's balance sheet. Smart investors calculate Adial Pharmaceuticals' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since Adial Pharmaceuticals' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Understanding that Adial Pharmaceuticals' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Adial Pharmaceuticals represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. However, Adial Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.